Advances in Zika virus vaccines and therapeutics: A systematic review

Abstract

Zika virus (ZIKV) is the causative agent of a viral infection that causes neurological complications in newborns and adults worldwide. Its wide transmission route and alarming spread rates are of great concern to the scientific community. Numerous trials have been conducted to develop treatment options for ZIKV infection. This review highlights the latest developments in the fields of vaccinology and pharmaceuticals developments for ZIKV infection. A systematic and comprehensive approach was used to gather relevant and up-to-date data so that inferences could be made about the gaps in therapeutic development. The results indicate that several therapeutic interventions are being tested against ZIKV infection, such as DNA vaccines, subunit vaccines, live-attenuated vaccines, virus-vector-based vaccines, inactivated vaccines, virus-like particles, and mRNA-based vaccines. In addition, approved anti-ZIKV drugs that can reduce the global burden are discussed. Although many vaccine candidates for ZIKV are at different stages of development, none of them have received Food and Drug Authority approval for use up to now. The issue of side effects associated with these drugs in vulnerable newborns and pregnant women is a major obstacle in the therapeutic pathway.

Keywords

Zika virus / Infection / Therapeutics / Antiviral agents / Vaccines / Therapies / Treatment / Novel therapeutic / Clinical management

References

[1] Ferraris P, Yssel H, Missé D. Zika virus infection: An update. Microb Infect 2019; 21: 353-360. doi: 10.1016/j.micinf.2019.04.005.

[2] Yadav AR, Mohite SK. A review on Zika virus infection. Res J Pharmac dos Form Tech 2020; 12: 295-297. doi: 10.5958/0975-4377.2020.00048.8.

[3] Chaw LL, Tuah NA, Wong JYY, Naing L. Knowledge, attitudes and practice survey on Zika virus infection among pregnant women in Brunei Darussalam. Asian Pac J Trop Med 2018; 11(11): 638.

[4] Zika Virus Individual Participant Data Consortium. The Zika virus individual participant data consortium: A global initiative to estimate the effects of exposure to Zika virus during pregnancy on adverse fetal, infant, and child health outcomes. Trop Med Infect Dis 2020; 5: 152. doi: 10.3390/tropicalmed5040152.

[5] Christian KM, Song H, Ming G. Pathophysiology and mechanisms of Zika virus infection in the nervous system. Annu Rev Neurosci 2019; 42: 249-269. doi: 10.1146/annurev-neuro-080317-062231.

[6] Pereira L. Congenital viral infection: Traversing the uterine-placental interface. Annu Rev Virol 2018; 5: 273-299. doi: 10.1146/annurev-virology-092917-043236.

[7] Masmejan S, Musso D, Vouga M, Pomar L, Dashraath P, Stojanov M, et al. Zika virus. Pathogens 2020; 9: 898. doi: 10.3390/pathogens9110898.

[8] Musso D, Ko AI, Baud D. Zika virus infection-after the pandemic. N Engl J Med 2019; 381: 1444-1457. doi: 10.1056/nejmra1808246.

[9] Wang Y, Ling L, Zhang Z, Marin-Lopez A. Current advances in Zika vaccine development. Vaccines 2022; 10: 1816. doi: 10.3390/vaccines10111816.

[10] McBroom K. A comparison of Zika virus and COVID-19: Clinical overview and public health messaging. J Midwifery Womens Health 2021; 66: 334-342. doi: 10.1111/jmwh.13230.

[11] Pattnaik A, Sahoo BR, Pattnaik AK. Current status of Zika virus vaccines: Successes and challenges. Vaccines 2020; 8: 266. doi: 10.3390/vaccines8020266.

[12] Yeasmin M, Molla MMA, Masud HMAA, Saif-Ur-Rahman KM. Safety and immunogenicity of Zika virus vaccine: A systematic review of clinical trials. Rev Med Virol 2022; 33(1): e2385. doi: 10.1002/rmv.2385.

[13] Cheong HC, Cheok YY, Chan YT, Sulaiman S, Looi CY, Alshanon AF, et al. Zika virus vaccine: The current state of affairs and challenges posed by antibody-dependent enhancement reaction. Viral Immunol 2022; 35: 586-596. doi: 10.1089/vim.2022.0082.

[14] Lunardelli VAS, Apostolico JDS, Fernandes ER, Santoro RD. Zika virusan update on the current efforts for vaccine development. Human Vac Immunotherap 2020; 17: 904-908. doi: 10.1080/21645515.2020.1796428.

[15] Poland GA, Ovsyannikova IG, Kennedy RB. Zika vaccine development: Current status. Mayo Clin Proceed 2019; 94: 2572-2586. doi: 10.1016/j.mayocp.2019.05.016.

[16] Li CJ, Huang PH, Chen HW, Chang SC. Development and characterization of mouse monoclonal antibodies targeting to distinct epitopes of Zika virus envelope protein for specific detection of Zika virus. Appl Microbiol Biotechnol 2021; 105: 4663-4673. doi: 10.1007/s00253-021-11364-1.

[17] de Melo Marques V, Santos CS, Santiago IG, Marques SM, das Graças Nunes Brasil M, Lima TT, et al. Neurological complications of congenital Zika virus infection. Pediat Neurol 2019; 91: 3-10. doi: 10.1016/j.pediatrneurol.2018.11.003.

[18] Magalhães ICL, Souza PFN, Marques LEC, Girão NM, Araújo FMC, Guedes MIF. New insights into the recombinant proteins and monoclonal antibodies employed to immunodiagnosis and control of Zika virus infection: A review. Int J Biol Macromol 2022; 200: 139-150. doi: 10.1016/j.ijbiomac.2021.12.196.

[19] Dussupt V, Modjarrad K, Krebs SJ. Landscape of monoclonal antibodies targeting Zika and dengue: Therapeutic solutions and critical insights for vaccine development. Front Immunol 2021; 11: 621043. doi: 10.3389/fimmu.2020.621043.

[20] Li Y, Chen Z, Wu L, Dai L, Qi J, Chai Y, et al. A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus. Innovation 2022; 3: 100323. doi: 10.1016/j.xinn.2022.100323.

[21] Yu L, Liu X, Ye X, Su W, Zhang X, Deng W, et al. Monoclonal antibodies against Zika virus NS1 protein confer protection via Fcyreceptor-dependent and -independent pathways. mBio 2021; 12(1): e03179-20. doi: 10.1128/mbio.03179-20.

[22] Haese NN, Roberts VHJ, Chen A, Streblow DN, Morgan TK, Hirsch AJ. Nonhuman primate models of Zika virus infection and disease during pregnancy. Viruses 2021; 13: 2088. doi: 10.3390/v13102088.

[23] Zhou K, Li C, Shi W, Hu X, Nandakumar KS, Jiang S, et al. Current progress in the development of Zika virus vaccines. Vaccines 2021; 9: 1004. doi: 10.3390/vaccines9091004.

[24] Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell 2021; 184: 1589-1603. doi: 10.1016/j.cell.2021.02.030.

[25] Knezevic I, Liu MA, Peden K, Zhou T, Kang HN. Development of mRNA vaccines: Scientific and regulatory issues. Vaccines 2021; 9: 81. doi: 10.3390/vaccines9020081.

[26] Lee LJ, Komarasamy TV, Adnan NAA, James W, Balasubramaniam V. Hide and seek: The interplay between Zika virus and the host immune response. Front Immunol 2021; doi: 10.3389/fimmu.2021.750365.

[27] Boivin B. Antiviral agents in development for Zika virus infections. Pharmaceutical 2019: 12: 101. doi: 10.3390/ph12030101.

[28] Schrauf S, Tschismarov R, Tauber E, Ramsauer K. Current efforts in the development of vaccines for the prevention of Zika and chikungunya virus infections. Front Immunol 2020; doi: 10.3389/fimmu.2020.00592.

[29] Guevarra Jr. L, De Sagon SP, De Asis Teh TR, Cruz MKDM, Capistrano NCC, Maria AJZS, et al. An immunoglobulin Y that specifically binds to an in silico-predicted unique epitope of Zika virus non-structural 1 antigen. Asian Pac J Trop Med 2022; 15(1): 35-43.

[30] Noorbakhsh F, Abdolmohammadi K, Fatahi Y, Dalili H, Rasoolinejad M, Rezaei F, et al. Zika virus infection, basic and clinical aspects: A review article. Iran J Public Health 2019; doi: 10.18502/ijph.v48i1.779.

[31] Adam A, Lee C, Wang T. Rational development of live-attenuated Zika virus vaccines. Pathogens 2023; 12: 194. doi: 10.3390/pathogens12020194.

[32] Chen Q, Wu J, Ye Q, Ma F, Zhu Q, Wu Y, et al. Treatment of human glioblastoma with a live attenuated Zika virus vaccine candidate. mBio 2019; doi: 10.1128/mbio.00433-19.

[33] Tai W, Chen J, Zhao G, Geng Q, He L, Chen Y, et al. Rational design of Zika virus subunit vaccine with enhanced efficacy. J Virol 2019; 93(17): e02187-18. doi: 10.1128/jvi.02187-18.

[34] National Library of Medicine (NIH). Vaccination trials against Zika infection; 2023. [Online]. Available from: https://clinicaltrials.gov/. [Accessed on 10 August 2023].

[35] Lundstrom K. Self-replicating vehicles based on negative strand RNA viruses. Can Gene Ther 2022; 30: 771-784. doi: 10.1038/s41417-022-00436-7.

[36] Hofmeyer KA, Bianchi KM, Wolfe DN. Utilization of viral vector vaccines in preparing for future pandemics. Vaccines 2022; 10: 436. doi: 10.3390/vaccines10030436.

[37] Thomas SJ, Barrett A. Zika vaccine pre-clinical and clinical data review with perspectives on the future development. Human Vac Immunotherap 2020; 16: 2524-2536. doi: 10.1080/21645515.2020.1730657.

[38] Shan C, Xie X, Shi PY. Zika virus vaccine: Progress and challenges. Cell Host Microbe 2018; 24: 12-17. doi: 10.1016/j.chom.2018.05.021.

[39] Thomas SJ, Barrett A. Zika vaccine pre-clinical and clinical data review with perspectives on the future development. Human Vac Immunotherap 2020; 16: 2524-2536. doi: 10.1080/21645515.2020.1730657.

[40] Bartsch SM, Asti L, Cox SN, Durham DP, Randall S, Hotez PJ, et al. What is the value of different Zika vaccination strategies to prevent and mitigate Zika outbreaks? J Infect Dis 2018; 220: 920-931. doi: 10.1093/infdis/jiy688.

[41] Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA vaccines protect against Zika virus infection. Cell 2017; 168: 1114-1125. doi: 10.1016/j.cell.2017.02.017.

[42] Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. Nat Rev Microbiol 2018; 16: 594-600. doi: 10.1038/s41579-018-0039-7.

[43] Cimica V, Galarza JM, Rashid S, Stedman TT. Current development of Zika virus vaccines with special emphasis on virus-like particle technology. Expert Rev Vacc 2021; 20: 1483-1498. doi: 10.1080/14760584.2021.1945447.

[44] Yaqub O, Luna JA, Moore DA, Yegros-Yegros A. Responding to a disease with resources from other diseases: Evidence from Zika vaccine research dynamics. Sci Pub Pol 2022; 49: 942-950. doi: 10.1093/scipol/scac040.

[45] Vuitika L, Prates-Syed WA, Silva JDQ, Crema KP, Côrtes N, Lira A, et al. Vaccines against emerging and neglected infectious diseases: An overview. Vaccines 2022; 10: 1385. doi: 10.3390/vaccines10091385.

[46] Castilho LR, Mattos NR, Abreu WS, Gutarra MLE. Virus-like particles (VLPs) as important tools for Flavivirus vaccine development. Biologics 2022; 2: 226-242. doi: 10.3390/biologics2040018.

[47] Vang L, Morello CS, Mendy J, Thompson D, Manayani D, Guenther B, et al. Zika virus-like particle vaccine protects AG129 mice and Rhesus macaques against Zika virus. PLoS Negl Trop Dis 2021; 15: e0009195. doi: 10.1371/journal.pntd.0009195.

[48] Leventhal SS, Meade-White K, Rao D, Haddock E, Leung J, Scott D, et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. eBioMedicine 2022; 82: 104188. doi: 10.1016/j.ebiom.2022.104188.

[49] Thomas SJ, Barrett A. Zika vaccine pre-clinical and clinical data review with perspectives on the future development. Human Vac Immunotherap 2020; 16: 2524-2536. doi: 10.1080/21645515.2020.1730657.

[50] Guevarra L Jr. , De Sagon SD, Teh TR, Cruz MKD, Capistrano NC, Maria AJS, et al. An immunoglobulin Y that specifically binds to an in silico-predicted unique epitope of Zika virus non-structural 1 antigen. Asian Pac J Trop Med 2022; 15(1): 35-43.

[51] Lathwal A, Kumar R, Raghava GPS. In-silico identification of subunit vaccine candidates against lung cancer-associated oncogenic viruses. Comput Biol Med 2021; 130: 104215. doi: 10.1016/j.compbiomed.2021.104215.

[52] Papukashvili D, Rcheulishvili N, Liu C, Ji Y, He Y, Wang PG. Self-amplifying RNA approach for protein replacement therapy. Int J Mol Sci 2022; 23: 12884. doi: 10.3390/ijms232112884.

[53] Scott P, de Lira LC, Matos S, Souza FM, Silva A, Quadros M. Therapeutic paths, care and assistance in the construction of ideas about maternity and childhood in the context of the Zika virus. Interface-Comunicação, Saúde, Educação 2018; 22: 673-684.

[54] Emanuel J, Callison J, Dowd KA, Pierson TC, Feldmann H, Marzi A. A VSV-based Zika virus vaccine protects mice from lethal challenge. Sci Rep 2018; 8: 11043. doi: 10.1038/s41598-018-29401-x.

[55] Yang R, Liu Q, Pang W, Gao F, Liang H, Zhang W, et al. Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in Rhesus macaques Vaccine. 2021; 39: 915-925. doi: 10.1016/j.vaccine.2020.12.077.

[56] Zoladek J, Burlaud-Gaillard J, Chazal M, Desgraupes S, Jeannin P, Gessain A, et al. Human claudin-derived peptides block the membrane fusion process of Zika virus and are broad Flavivirus inhibitors. Microbiol Spectrm 2022; 10(5): e0298922. doi: 10.1128/spectrum.02989-22.

[57] Nandy A, Manna S, Basak SC. Computational methodology for peptide vaccine design for Zika virus: A bioinformatics approach. Immunoinformatics 2020; 2131: 17-30.

[58] Surnar B, Kamran MZ, Shah AS, Basu U, Kolishetti N, Deo S, et al. Orally administrable therapeutic synthetic nanoparticle for Zika virus. ACS Nano 2019; 13: 11034-11048. doi: 10.1021/acsnano.9b02807.

[59] Jackman JA, Costa VV, Park S, Real ALCV, Park JH, Cardozo PL, et al. Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide. Nat Mater 2018; 17: 971-977. doi: 10.1038/s41563-018-0194-2.

[60] Han Y, Mesplède T. Investigational drugs for the treatment of Zika virus infection: A preclinical and clinical update. Expert Opin Investig Drugs 2018; 27: 951-962. doi: 10.1080/13543784.2018.1548609.

[61] Katzelnick LC, Narvaez C, Arguello S, Lopez Mercado B, Collado D, Ampie O, et al. Zika virus infection enhances future risk of severe dengue disease. Science 2020; 369: 1123-1128. doi: 10.1126/science.abb6143.

[62] Song W, Zhang H, Zhang Y, Li R, Han Y, Lin Y, et al. Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection. Front Med 2020; 15: 404-415. doi: 10.1007/s11684-021-0834-9.

[63] Kazmi SS, Ali W, Bibi N, Nouroz F. A review on Zika virus outbreak, epidemiology, transmission and infection dynamics. J Biol Res- Thessaloniki 2020; doi: 10.1186/s40709-020-00115-4.

[64] Abrams RPM, Yasgar A, Teramoto T, Lee MH, Dorjsuren D, Eastman RT, et al. Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceed Nat Acad Sci 2020; 117: 31365-31375. doi: 10.1073/pnas.2005463117.

[65] Conners EE, Lee EH, Thompson CN, McGibbon E, Rakeman JL, Iwamoto M, et al. Zika virus infection among pregnant women and their neonates in New York city, January 2016-June 2017. Obstet Gynecol 2018; 132: 487-495. doi: 10.1097/aog.0000000000002737.

[66] Malik S, Niazi M, Khan M, Rauff B, Anwar S, Amin F, et al. Cytotoxicity study of gold nanoparticle synthesis using Aloe vera, honey, and Gymnema sylvestre leaf extract. ACS Omega 2023; 8: 6325-6336. doi: 10.1021/acsomega.2c06491.

[67] Sehajpal S, Saraswat R, Verma N. Pharmacognostical profile of Gymnema sylvestre and its anti-hyperglycemic activity. J Pharmaceut Res Interntl 2021; doi: 10.9734/jpri/2021/v33i58a34128.

[68] Benazzato C, Russo FB, Beltrão-Braga PCB. An update on preclinical pregnancy models of Zika virus infection for drug and vaccine discovery. Expert Opin Drug Discover 2021; 17: 19-25. doi: 10.1080/17460441.2021.1973999.

[69] Zhang R, Fu Y, Cheng M, Ma W, Zheng N, Wang Y, et al. sEVsRVG selectively delivers antiviral siRNA to fetus brain, inhibits ZIKV infection and mitigates ZIKV-induced microcephaly in mouse model. Mol Ther 2022; 30: 2078-2091. doi: 10.1016/j.ymthe.2021.10.009.

[70] Stephenson KE, Tan CS, Walsh SR, Hale A, Ansel JL, Kanjilal DG, et al. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: A single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis 2020; 20: 1061-1070.

[71] Dussupt V, Sankhala RS, Gromowski GD, Donofrio G, De La Barrera RA, Larocca RA, et al. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med 2020; 26: 228-235.

[72] Han HH, Diaz C, Acosta CJ, Liu M, Borkowski A. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: An observer-blind, randomised, phase 1 trial. Lancet Infect Dis 2021; 21: 1282-1292.

[73] Oh HS, Yoon JW, Lee S, Kim SO, Hong SP. A purified inactivated vaccine derived from Vero cell-adapted Zika virus elicits protection in mice. Virology 2021; 560: 124-130.

[74] Pergolizzi J, LeQuang JA, Umeda-Raffa S, Fleischer C, Pergolizzi J, Pergolizzi C, et al. The Zika virus: Lurking behind the COVID-19 pandemic? J Clinic Pharm Therapeu 2020; 46: 267-276. doi: 10.1111/jcpt.13310.

[75] Ledur PF, Karmirian K, Pedrosa C, da SG, Souza LRQ, Assis-de-Lemos G, et al. Zika virus infection leads to mitochondrial failure, oxidative stress and DNA damage in human iPSC-derived astrocytes. Sci Rep 2020; doi: 10.1038/s41598-020-57914-x.

[76] Bautista LE. Zika virus infection and risk of Guillain-Barré syndrome: A meta-analysis. J Neurol Sci 2019; 403: 99-105. doi: 10.1016/j.jns.2019.06.019.

[77] Ventura PA, Lage MLC, de Carvalho AL, Fernandes AS, Taguchi TB, Nascimento-Carvalho CM. Early gross motor development among Brazilian children with microcephaly born right after Zika virus infection outbreak. J Development Behavior Pediat 2020; 41: 134-140. doi: 10.1097/dbp.0000000000000722.

[78] Bisar R, Dharman D. Zika virus outbreak, epidemiology, transmission and infection dynamics: A review article. Asian J Pharma Health Sci 2021; 11: 2497-2500. doi: 10.5530/ajphs.2021.11.13.

[79] Mitchell PK, Mier-y-Teran-Romero L, Biggerstaff BJ, Delorey MJ, Aubry M, Cao-Lormeau VM, et al. Reassessing serosurvey-based estimates of the symptomatic proportion of Zika virus infections. Am J Epidemiol 2018; 188: 206-213. doi: 10.1093/aje/kwy189.

[80] World Health Organization. Laboratory testing for Zika virus and dengue virus infections: Interim guidance. 2022; [Online]. Available from: https://www.who.int/publications-detail-redirect/WHO-ZIKV_DENV-LAB-2022.1. [Accessed on 10 August 2023].

[81] Venturi G, Fortuna C, Alves RM, do Prado Paschoal AGP, da Silva Júnior PJ, Remoli ME, et al. Epidemiological and clinical suspicion of congenital Zika virus infection: Serological findings in mothers and children from Brazil. J Med Virol 2019; 91: 1577-1583. doi: 10.1002/jmv.25504.

[82] Singh A, Ray A, Mishra R, Biswal PK, Yadav R, Ghatuary SK. Phyto-phospholipid complexes: Innovative approach to enhance the bioavailability and therapeutic efficacy of herbal extract. Pharma Biosci J 2020; doi: 10.20510/ukjpb/8/i4/1593521611.

[83] Diamond MS, Ledgerwood JE, Pierson TC. Zika virus vaccine development: Progress in the face of new challenges. Annu Rev Med 2019; 70: 121-135. doi: 10.1146/annurev-med-040717-051127.

[84] Rice ME, Galang RR, Roth NM, Ellington SR, Moore CA, Valencia-Prado M, et al. Vital signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection-U. S. territories and freely associated states, 2018. MMWR Morb Mort Weekly Rep 2018; 67(31): 858-867. doi: 10.15585/mmwr.mm6731e1.

[85] Wen J, Shresta S. Antigenic cross-reactivity between Zika and dengue viruses: Is it time to develop a universal vaccine? Cur Opin Immunol 2019; 59: 1-8. doi: 10.1016/j.coi.2019.02.001.

[86] Pierson TC, Diamond MS. The emergence of Zika virus and its new clinical syndromes. Nature 2018; 560: 573-581. doi: 10.1038/s41586-018-0446-y.

[87] Vouga M, Chiu YC, Pomar L, de Meyer SV, Masmejan S, Genton B, et al. Dengue, Zika and chikungunya during pregnancy: Pre- and post-travel advice and clinical management. J Travel Med 2019; doi: 10.1093/jtm/taz077.

[88] Vannice KS, Cassetti MC, Eisinger RW, Hombach J, Masmejan S, Genton B, et al. Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. Vaccine 2019; 37: 863-868. doi: 10.1016/j.vaccine.2018.12.040.

[89] Silva NM, Santos NC, Martins IC. Dengue and Zika viruses: Epidemiological history, potential therapies, and promising vaccines. Trop Med Infect Dis 2020; 5: 150. doi: 10.3390/tropicalmed5040150.

[90] Yang X, Zhang X, Zhao X, Yuan M, Zhang K, Dai J, et al. Antibody-dependent enhancement: “Evil” antibodies favorable for viral infections. Viruses 2022; 14: 1739. doi: 10.3390/v14081739.

[91] Malik S, Muhammad K, Waheed Y. Nanotechnology: A revolution in modern industry. Molecules 2023; 28: 661. doi: 10.3390/molecules28020661.

[92] Malik S, Muhammad K, Waheed Y. Emerging applications of nanotechnology in healthcare and medicine. Molecules 2023; 28: 6624. doi: 10.3390/molecules28186624.

[93] Waheed Y, Sah R, Muhammad K. Recent developments in vaccines for viral diseases. Vaccines 2023; 11: 198. doi: 10.3390/vaccines11020198.

[94] Santiago HC, Pereira-Neto TA, Gonçalves-Pereira MH, Terzian ACB, Durbin AP. Peculiarities of Zika immunity and vaccine development: Lessons from dengue and the contribution from controlled human infection model. Pathogens 2022; 11: 294. doi: 10.3390/pathogens11030294.